Literature DB >> 28124012

Liraglutide's use in treatment of non-alcoholic fatty liver: an evaluation of the non-alcoholic steatohepatitis study.

Debra A Guss1, Smruti R Mohanty1.   

Abstract

Entities:  

Year:  2016        PMID： 28124012      PMCID： PMC5218908          DOI： 10.21037/hbsn.2016.11.09

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  6 in total

1.  The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal
Journal:  Hepatology       Date:  2012-06       Impact factor: 17.425

2.  Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts.

Authors:  Paul Angulo
Journal:  Hepatology       Date:  2011-06       Impact factor: 17.425

Review 3.  Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.

Authors:  Siddharth Singh; Rohan Khera; Alina M Allen; M Hassan Murad; Rohit Loomba
Journal:  Hepatology       Date:  2015-10-01       Impact factor: 17.425

4.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

Authors:  Robert J Wong; Maria Aguilar; Ramsey Cheung; Ryan B Perumpail; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  Gastroenterology       Date:  2014-11-25       Impact factor: 22.682

5.  Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: Does the underlying health status play a role?

Authors:  M Dietrich; P F Jacques; M J Pencina; K Lanier; M J Keyes; G Kaur; P A Wolf; R B D'Agostino; R S Vasan
Journal:  Atherosclerosis       Date:  2008-12-24       Impact factor: 5.162

6.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

Authors:  Matthew James Armstrong; Piers Gaunt; Guruprasad P Aithal; Darren Barton; Diana Hull; Richard Parker; Jonathan M Hazlehurst; Kathy Guo; George Abouda; Mark A Aldersley; Deborah Stocken; Stephen C Gough; Jeremy W Tomlinson; Rachel M Brown; Stefan G Hübscher; Philip N Newsome
Journal:  Lancet       Date:  2015-11-20       Impact factor: 79.321
  6 in total
  1 in total

1.  A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D).

Authors:  Samit Ghosal; Debasis Datta; Binayak Sinha
Journal:  Sci Rep       Date:  2021-11-11       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.